Table 2.

Treatment-related adverse events related to ramucirumab and docetaxel among patients in the UM Cohort.

Toxicity Variable	All Grades (%)	Grade 3+ (%)
Hypertension (Ram)	2 (5.7)	–
Proteinuria (Ram)	2 (5.7)	–
Bleeding (Ram)	1 (2.9)	1 (2.9)
Fatigue (Ram)	1 (2.9)	–
Dose-reduction of Ram	1 (2.9)	1 (2.9)
Fatigue (Doc)	15 (42.9)	1 (2.9)
Skin/nail changes (Doc)	3 (8.6)	–
Myalgias (Doc)	1 (2.9)	1 (2.9)
Neutropenia (Doc)	2 (5.7)	1 (2.9)
Anemia (Doc)	4 (11.4)	–
Neuropathy (Doc)	4 (11.4)	1 (2.9)
Cough/COPD Exacerbation (Doc)	2 (5.7)	–
Dose-reduction of Doc	2 (5.7)	2 (5.7)
Dose-reduction of Ram + Doc	2 (5.7)	2 (5.7)
Arthralgia (IO)	1 (2.9)	–

This symbol means no value.